SAM #DARPA-PS-26-124

DARPA RAPIID Program: Shelf-Stable Blood Analog Components and Diagnostics for Trauma Care

DARPA is seeking innovative solutions for the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program, focused on next-generation trauma care for military and austere environments. - Government Buyer: - Defense Advanced Research Projects Agency (DARPA), Biological Technologies Office (BTO) - Products/Services Requested: - Development of shelf-stable blood analog components: - Oxygen carrier (TA-1) - Platelet-derived products, shelf-stable platelets, or platelet-like particles (TA-1) - Dried plasma (TA-1) - Point-of-care diagnostic/device for blood analog detection and transfusion support (TA-2) - Regulatory advancement and program infrastructure services (TA-3): - GLP pre-clinical testing, regulatory submissions (IND/IDE), clinical trial planning, GMP manufacturing readiness - Commercialization and sustainment services (TA-4): - Market research, business planning, procurement strategy, manufacturing scalability, transition support - Research and development program for biomass separation and conversion (related R&D scope) - Project management, technical and financial reporting, milestone verification, and site visits - Unique/Notable Requirements: - Solutions must be shelf-stable, fieldable, and eliminate cold chain and donor logistics - Proposals must address technical, regulatory, and commercialization milestones - Emphasis on manufacturability, scalability, and post-program commercial viability - Milestone-based payments and deliverables, with detailed reporting and site visits - Compliance with federal regulations, intellectual property, data rights, and cybersecurity requirements - No specific OEMs or commercial vendors are named; the opportunity is open to a wide range of technology developers and research organizations.

Description

The Resuscitation and Prevention of Ischemia-induced Dysfunction (RAPIID) program seeks to deliver a transformative, end-to-end resuscitation system that redefines far-forward trauma care. RAPIID aims for this system to be fieldable, usable, and scalable, providing a capability equivalent or superior to stored whole blood in early resuscitation while removing dependence on cold chain and donor logistics. RAPIID seeks to do this by developing a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines (CPGs). To maximize post-program viability of developed products, RAPIID will develop and execute effective regulatory and commercialization strategies and accelerate advanced development through technology readiness level (TRL) 7 (Scale-up and Phase II Clinical Trials)1 for blood analog components and TRL 8 (Clinical Studies)2 for devices and diagnostics. This solicitation is to request proposals addressing ONLY Phase 1 of Task Area (TA)-1 and/or TA-2.

View original listing